Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Analyst consensus: Hold — Thirteen analysts rate Amicus Therapeutics an average "Hold" (1 sell, 9 holds, 3 buys) with a mean 12-month price target of about $15.39.
• Mixed quarterly results: Q reporting showed an EPS miss ($0.10 vs. $0.13 expected) but revenue rose 23.7% year-over-year to $185.21M, while the company remains unprofitable with a negative net margin.
• Insider and institutional moves: CEO Bradley Campbell sold 22,500 shares (reducing his stake) and institutions like Invesco materially increased positions (Invesco now owns ~1.26M shares after adding ~797K shares).

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have received an average recommendation of "Hold" from the thirteen analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $15.3889.

Several equities research analysts recently commented on FOLD shares. Zacks Research cut Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 26th. Guggenheim cut Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of Amicus Therapeutics in a research note on Friday, March 27th. Cantor Fitzgerald cut Amicus Therapeutics from an "overweight" rating to a "hold" rating and lowered their price target for the company from $21.00 to $14.50 in a research note on Friday, December 19th. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $14.50 price target (down from $16.00) on shares of Amicus Therapeutics in a research note on Thursday, January 22nd.

Amicus Therapeutics Trading Up 0.1%

Shares of NASDAQ FOLD opened at $14.47 on Friday. The stock has a market cap of $4.54 billion, a price-to-earnings ratio of -180.88 and a beta of 0.48. The business has a 50 day simple moving average of $14.37 and a 200 day simple moving average of $12.01. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $14.48. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.88 and a current ratio of 2.84.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last announced its quarterly earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.03). The firm had revenue of $185.21 million during the quarter, compared to the consensus estimate of $185.00 million. Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The company's quarterly revenue was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.09 EPS. On average, research analysts predict that Amicus Therapeutics will post 0.15 earnings per share for the current fiscal year.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 22,500 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $14.35, for a total transaction of $322,875.00. Following the completion of the sale, the chief executive officer owned 998,680 shares of the company's stock, valued at $14,331,058. This represents a 2.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Amicus Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Amicus Therapeutics during the fourth quarter worth approximately $14,240,000. Caitong International Asset Management Co. Ltd bought a new stake in Amicus Therapeutics during the fourth quarter worth approximately $60,000. Seven Fleet Capital Management LP bought a new stake in Amicus Therapeutics during the fourth quarter worth approximately $1,175,000. Virtu Financial LLC boosted its position in Amicus Therapeutics by 177.7% during the fourth quarter. Virtu Financial LLC now owns 117,063 shares of the biopharmaceutical company's stock worth $1,667,000 after purchasing an additional 74,902 shares during the period. Finally, Invesco Ltd. boosted its position in Amicus Therapeutics by 172.6% during the fourth quarter. Invesco Ltd. now owns 1,259,225 shares of the biopharmaceutical company's stock worth $17,931,000 after purchasing an additional 797,255 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics NASDAQ: FOLD is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company's lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.